Drug Interactions:Strong and moderate CYP3A4 inhibitors increase VRAYLAR concentrations, so VRAYLAR dose reduction is recommended. Concomitant use with CYP3A4 inducers is not recommended. Adverse Reactions:The most common adverse reactions in clinical trials (≥5% and at least twice the rate of placeb...